SARS-CoV-2 disrupts clinical research: the role of a rare disease-specific trial network

Rare disease patients may suffer delayed access to new drugs as SARS-CoV-2 is disrupting clinical trials. This survey demonstrates that the European Cystic Fibrosis Clinical Trials Network is ideally placed to track and address such disruption. https://bit.ly/3hCw5dq

Detalles Bibliográficos
Autores principales: van Koningsbruggen-Rietschel, Silke, Dunlevy, Fiona, Bulteel, Veerle, Downey, Damian G., Dupont, Lieven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2020
Materias:
Agora
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7411273/
https://www.ncbi.nlm.nih.gov/pubmed/32764115
http://dx.doi.org/10.1183/13993003.02114-2020
_version_ 1783568343314202624
author van Koningsbruggen-Rietschel, Silke
Dunlevy, Fiona
Bulteel, Veerle
Downey, Damian G.
Dupont, Lieven
author_facet van Koningsbruggen-Rietschel, Silke
Dunlevy, Fiona
Bulteel, Veerle
Downey, Damian G.
Dupont, Lieven
author_sort van Koningsbruggen-Rietschel, Silke
collection PubMed
description Rare disease patients may suffer delayed access to new drugs as SARS-CoV-2 is disrupting clinical trials. This survey demonstrates that the European Cystic Fibrosis Clinical Trials Network is ideally placed to track and address such disruption. https://bit.ly/3hCw5dq
format Online
Article
Text
id pubmed-7411273
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-74112732020-08-12 SARS-CoV-2 disrupts clinical research: the role of a rare disease-specific trial network van Koningsbruggen-Rietschel, Silke Dunlevy, Fiona Bulteel, Veerle Downey, Damian G. Dupont, Lieven Eur Respir J Agora Rare disease patients may suffer delayed access to new drugs as SARS-CoV-2 is disrupting clinical trials. This survey demonstrates that the European Cystic Fibrosis Clinical Trials Network is ideally placed to track and address such disruption. https://bit.ly/3hCw5dq European Respiratory Society 2020-09-17 /pmc/articles/PMC7411273/ /pubmed/32764115 http://dx.doi.org/10.1183/13993003.02114-2020 Text en Copyright ©ERS 2020 https://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
spellingShingle Agora
van Koningsbruggen-Rietschel, Silke
Dunlevy, Fiona
Bulteel, Veerle
Downey, Damian G.
Dupont, Lieven
SARS-CoV-2 disrupts clinical research: the role of a rare disease-specific trial network
title SARS-CoV-2 disrupts clinical research: the role of a rare disease-specific trial network
title_full SARS-CoV-2 disrupts clinical research: the role of a rare disease-specific trial network
title_fullStr SARS-CoV-2 disrupts clinical research: the role of a rare disease-specific trial network
title_full_unstemmed SARS-CoV-2 disrupts clinical research: the role of a rare disease-specific trial network
title_short SARS-CoV-2 disrupts clinical research: the role of a rare disease-specific trial network
title_sort sars-cov-2 disrupts clinical research: the role of a rare disease-specific trial network
topic Agora
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7411273/
https://www.ncbi.nlm.nih.gov/pubmed/32764115
http://dx.doi.org/10.1183/13993003.02114-2020
work_keys_str_mv AT vankoningsbruggenrietschelsilke sarscov2disruptsclinicalresearchtheroleofararediseasespecifictrialnetwork
AT dunlevyfiona sarscov2disruptsclinicalresearchtheroleofararediseasespecifictrialnetwork
AT bulteelveerle sarscov2disruptsclinicalresearchtheroleofararediseasespecifictrialnetwork
AT downeydamiang sarscov2disruptsclinicalresearchtheroleofararediseasespecifictrialnetwork
AT dupontlieven sarscov2disruptsclinicalresearchtheroleofararediseasespecifictrialnetwork

Ejemplares similares